文献速递神经技术与安全CTMR

定量肌肉质量生物标志物是原发性中枢神经系统淋巴瘤的独立预后因素:L3骨骼肌指数与颞肌厚度的作用

Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness.
PubMed 文献 · Eur J Radiol · 2021-09-02

多变量Cox回归显示,低L3-SMI或低TMT患者无进展生存和总生存均显著更差,提示定量肌肉质量评估有助于识别预后不良的高危患者。

要点

  • L3-SMI与TMT均可独立预测PCNSL患者的无进展生存和总生存。
  • 低L3-SMI或低TMT者预后显著更差,多变量分析中风险比最高达4.93。
  • 腹部CT与脑3D-T1 MR可机会性评估肌肉质量,辅助预后分层。

核心结论

  • 定量肌肉质量评估(L3-SMI和TMT)是有前景的工具,可识别PCNSL预后不良的高危患者。

研究设计与样本

  • L3-SMI在腹部CT上计算,TMT在脑高分辨率3D-T1加权MR图像上计算,均采用预设的验证方法。
  • 采用预设的性别特异性截断值将患者分为不同风险类别。
  • 生存分析采用Kaplan-Meier曲线、log-rank检验、单变量和多变量Cox回归模型,并校正年龄、性别和体能状态。

诊断标准与关键数值

  • 采用预设的性别特异性截断值划分L3-SMI和TMT高低风险组。
  • 13例(30%)患者L3-SMI低于预设截断值,11例(26%)患者TMT低于预设截断值。
  • 低L3-SMI组无进展生存HR 4.40(95%CI 1.66-11.61,p=0.003),总生存HR 3.16(95%CI 1.09-9.11,p=0.034)。
  • 低TMT组无进展生存HR 4.40(95%CI 1.68-11.49,p=0.003),总生存HR 4.93(95%CI 1.78-13.65,p=0.002)。

临床应用与阅片要点

  • 阅片时可利用腹部CT机会性测量L3-SMI,利用脑3D-T1 MR测量TMT,辅助PCNSL预后分层。
  • 注意采用预设的性别特异性截断值判断肌肉质量降低,避免自行设定阈值。

局限性

  • 单中心研究设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To investigate the role of quantitative muscle biomarkers assessed with skeletal muscle index at the third lumbar vertebra (L3-SMI) and temporal muscle thickness (TMT) in predicting progression-free and overall survival in patients with primary central nervous system lymphoma (PCNSL) undergoing first-line high-dose methotrexate-based chemotherapy.

METHODS: L3-SMI and TMT were calculated on abdominal CT and brain high-resolution 3D-T1-weighted MR images, respectively, using predefined validated methods. Standardized sex-specific cut-off values were used to divide patients in different risk categories. Kaplan-Meier plots were calculated, and survival analysis was performed using log-rank tests, univariate, and multivariable Cox-regression models, calculating hazard ratios (HR) and 95% confidence intervals (CI), also adjusting for potential confounders (age, sex, and performance status).

RESULTS: Forty-three patients were included in this study. Median follow-up was 23 months (interquartile range 12-40); at median follow-up, rates of progression-free and overall survival for the cohort were 46% and 57%, respectively. Thirteen (30%) and 11 (26%) patients showed L3-SMI or TMT values below the predefined cut-offs. In Cox-regression multivariable analysis patients with low L3-SMI or TMT showed significantly worse progression-free (HR 4.40, 95% CI 1.66-11.61, p = 0.003; HR 4.40, 95% CI 1.68-11.49, p = 0.003, respectively) and overall survival (HR 3.16, 95% CI 1.09-9.11, p = 0.034; HR 4.93, 95% CI 1.78-13.65, p = 0.002, respectively) compared to patients with high L3-SMI or TMT.

CONCLUSIONS: Quantitative muscle mass evaluation assessed by both L3-SMI and TMT is a promising tool to identify PCNSL patients at high risk of negative outcome. Confirmatory studies on larger independent series are warranted.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Leone R, Sferruzza G, Calimeri T, et al. Quantitative muscle mass biomarkers are independent prognosis factors in primary central nervous system lymphoma: The role of L3-skeletal muscle index and temporal muscle thickness. Eur J Radiol. 2021. PMID: 34492625. doi:10.1016/j.ejrad.2021.109945

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。